Global Outlook 2024 Report


Like this article?

Sign up to our free newsletter

Sheridan Capital Partners invests in RS&A

Sheridan Capital Partners (Sheridan) has made an investment in RS&A, an established medical device independent service provider (ISP).

Sheridan has invested alongside RSA’s founding team, which retains a meaningful ownership stake in the business and will remain active in the operations of the Company.

Founded in 1995 by Carl Hill and Kenneth Wolff, RSA has scaled from a regional service team to a well-established independent service provider, serving a blue-chip customer base within radiation therapy. RSA specialises in a wide range of support services needed to maintain radiotherapy equipment used in the treatment of cancer patients, most notably medical linear accelerators (LINACs).

Like this article? Sign up to our free newsletter